MENU
MNPR
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Monopar Therapeutics (MNPR) Earnings Date & Reports
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology... Show more
A.I. Advisor
published Earnings
MNPR is expected to report earnings to rise 29.97% to -80 cents per share on November 06
Q3'26
Est.
$-0.81
Q2'26
Beat
by $0.11
Q4'25
Missed
by $0.53
Q3'25
Missed
by $0.39
Q2'25
Missed
by $0.26
The last earnings report on August 12 showed earnings per share of -62 cents, beating the estimate of -73 cents. With 34.03K shares outstanding, the current market capitalization sits at 561.94M.
View a ticker or compare two or three
VS
VS
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a clinical stage biopharmaceutical company, which engages in building a drug development pipeline of oncology therapeutics in late preclinical and clinical development stages
Industry Biotechnology
Industry
N/A
Address
1000 Skokie Boulevard
Phone
+1 847 388-0349
Employees
22
Web
https://www.monopartx.com